Algert Global’s Fortress Biotech FBIO Stock Holding History

Algert Global’s Portfolio FBIO Stock Details FBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-837	Closed	-$17K	–	1262
2022 Q1	$17K	Buy	+837	New	+$22.9K	﹤0.01%	1160

Other funds holding FBIO

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OMC

Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

SAM

Shikiar Asset Management New York $396M AUM 41.06% 1-Year Est. Return

CPWM LLC Seattle, Washington $1.06B AUM 14.49% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

Algert Global's FBIO Position: Q2 2022 in Review

Algert Global sold out of Fortress Biotech (FBIO) in Q2 2022, closing a stake of 837 shares — an estimated $17K sold.

Algert Global first reported a position in FBIO in Q1 2022 and held it in 1 quarter. The position peaked at $17K in Q1 2022. 66 funds tracked by Wall St. Rank hold FBIO as of Q2 2022.

Algert Global reported no remaining Fortress Biotech position as of Q2 2022 after selling out during the quarter.
Algert Global sold 837 Fortress Biotech shares in Q2 2022, an estimated $17K.
Algert Global first reported a position in Fortress Biotech in Q1 2022 and held it in 1 quarter.
Algert Global's Fortress Biotech position peaked at $17K in Q1 2022.
66 funds tracked by Wall St. Rank held Fortress Biotech as of Q2 2022.

Based on Algert Global's 13F filing for Q2 2022, filed 15 Aug 2022.